Miscellaneous News

RSS

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Researchers at the Leiden University Medical Center demonstrated that low-micromolar concentrations of 6′,6′-difluoro24 aristeromycin (DFA), an adenosine nucleoside analog, strongly inhibits the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) in a cell-based infection assay.

25 May 2021

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

In a recent study by researchers in Mexico, Russia and Spain, silver nanoparticles (AgNPs) were found to inhibit SARS-CoV-2 in healthcare workers. They propose a non-pharmaceutical public health intervention consisting of mouthwash and nose rinse with an AgNPs solution to reduce morbidity among healthcare personnel exposed to the SARS-CoV-2 virus.

24 May 2021

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

While drug repurposing has been explored in the context of the current coronavirus disease 2019 (COVID-19) pandemic, the success of this strategy has been limited so far. A new study, released as a preprint on the medRxiv* server, describes a new method of identifying a promising hit among drugs already in use.

24 May 2021

How do common mutations in SARS-CoV-2’s spike affect its binding affinity with host cell receptors?

Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.

21 May 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

Risk factors for rare COVID-19 complications in children (MIS-C)

While the earlier waves of COVID-19 relatively spared children, some of the affected children have developed a systemic inflammatory condition, with occasionally fatal outcomes. Called multisystem inflammatory syndrome in children (MIS-C), its pathogenesis and risk factors are the subject of a new study on the medRxiv* preprint server.

21 May 2021

Can SARS-CoV-2 trigger amyloidosis?

A new study, released as a preprint on the bioRxiv* server, describes the results of an analysis of the role played by the virus in amyloid formation, with its subsequent effects on the health of various organs and of the whole organism.

21 May 2021

Masks and physical distancing could reduce SARS-CoV-2 spread to 1% among essential food plant workers, says study

The food supply is an essential service. Yet, workers in this industry are at high risk of acquiring infection with the novel coronavirus in their workplace unless proper mitigation measures are put in place. A new study, released as a preprint on the medRxiv* server, shows that the risk of infection may be reduced to less than 1% with proper precautions.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

North America has 87% of all unique SARS-CoV-2 S protein variants in the NCBI database among six continents

Recently, a team of researchers from various countries analyzed the unique variants of S proteins across six continents, including Africa, Asia, Oceania, Europe, South America, and North America. They wanted to characterize the unique S protein variants embedded in SARS-CoV-2 genomes infecting millions of people globally.

20 May 2021

COVID-19 cases in summer 2020 was not as low as previously thought, new genome-based model suggests

Many have attributed the low number of coronavirus disease 2019 (COVID-19) cases in the summer of 2020 to hot weather or increased outdoor activities. But a new study from researchers in Germany suggests this might not have been the case.

20 May 2021

How is COVID-19 changing hunting patterns during lockdown in India?

To examine the real impact of COVID-19 lockdown on wildlife hunting across India, a team of researchers conducted a study from March-May 2020. Using media reports and online interviews with wildlife researchers, enforcement staff and NGO employees, the research team explored the change in hunting patterns and the socio-economic and institutional factors underlying these changes.

20 May 2021

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A team of researchers recently cross-tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to assess their neutralization activity against different variants. The team recently released their findings as a preprint on the medRxiv* server.

20 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

What can ancient feces tell us about the evolution of the human gut microbiome?

Researchers at the Section on Pathophysiology and Molecular Pharmacology, Joslin Diabetes Center in Boston, Massachusetts, analyzed microbial DNA found in indigenous human paleofeces (desiccated excrement) from dry caves in northern Mexico and Utah. They found that the ancient human gut microbiome is similar to those of modern-day people from non-industrialized populations.

14 May 2021

Do labels on commercial kefir products report microbial levels correctly?

A recent study in the journal JDS Communications reports the results of an analysis of five brands of kefir on the US market, indicating the need for stricter regulation of this field.

14 May 2021

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.

13 May 2021

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

A recent report on the medRxiv* preprint server suggests that a single dose of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine could elicit higher titers of neutralizing antibodies, effectively acting as a booster dose, in people who have already been infected by the SARS-CoV-2.

13 May 2021

Miscellaneous News

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

How do common mutations in SARS-CoV-2’s spike affect its binding affinity with host cell receptors?

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Risk factors for rare COVID-19 complications in children (MIS-C)

Can SARS-CoV-2 trigger amyloidosis?

Masks and physical distancing could reduce SARS-CoV-2 spread to 1% among essential food plant workers, says study

Facets of SARS-CoV-2 infection and animal models

North America has 87% of all unique SARS-CoV-2 S protein variants in the NCBI database among six continents

COVID-19 cases in summer 2020 was not as low as previously thought, new genome-based model suggests

How is COVID-19 changing hunting patterns during lockdown in India?

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

What can ancient feces tell us about the evolution of the human gut microbiome?

Do labels on commercial kefir products report microbial levels correctly?

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News